The growth of pharmaceutical expenditure and its prediction is a major concern for policy makers and health care managers. This paper explores different predictive models to estimate future drug expenses, using demographic and morbidity individual information from an integrated healthcare delivery organization in Catalonia for years 
Introduction
The growth of pharmaceutical expenditures is a current major concern for health policy makers in Spain. There, drug expenditures have grown in the last decade to represent around 23% of total health expenditures in 2004 [1] . As a consequence, the policy agenda is focused on how these increasing expenditures should be financed and consider issues like copayment, how to selectively finance medicines, or introducing price competition in generic drugs [2] . This paper proposes risk adjustment as a tool for predicting drug expenditures and for setting the premiums for pharmaceutical benefits using individual data. We apply several specifications for the estimation beyond the usual linear specification and compare our predictability results with others from the literature.
The analysis of pharmaceutical consumption should start with information about what is prescribed and for which pathology, what is consumed and how much it costs at individual level. In order to establish a relationship between pharmaceutical consumption and morbidity, we need two essential sources: individual information about pharmaceutical costs and morbidity. Up to now, these sources have been difficult to get and therefore, the debate has focused on averages and growth rates, providing little information to take decisions at policy and management level [3] .
Although several studies have used pharmacy data to predict total health care costs [4, 5, 6, 7, 8, 9] , only a few have addressed the issue of predictability of drug spending. A feasible explanation is that usually private insurers do not offer free standing drug benefits, and public programs offering those benefits have not developed private riskbased contracts [10] . Using only demographic information and past cost, two studies in the 1990s [11, 12] showed the highly persistent behavior of drug expenditures and the low predictive power of using only demographic information (from 02 . 0
). Adding health status (morbidity) information through the diagnosis cost group/hierarchical condition category (DCG/HCC) risk-adjustment methodology [10, 13] , different prospective models obtain higher predicting power with an R 2 between 0.10 and 0.24, while adding lag expenditures raised it to 0.55 [10] . Lastly, Pharmacy Categories (Rx-Groups) have also been used to predict pharmacy costs [13] obtaining an 2 R near 0.50, and therefore explaining almost half of the variation of the cost in the subsequent year.
This paper fits in the literature predicting drug expenditures using a classification system for health status that allows to understand population morbidity [14, 15] . We apply the Clinical Risk Groups (CRGs) classification system, which allows classifying individuals in mutually exclusive categories attending to their clinical conditions. It differs from the DCG/HCC methodology, that allows multiples categories for each individual. The CRG methodology uses information from the encounters between the health system and the patients, and allocates a severity level to each patient [16] . The uniqueness of the CRGs compared to other methods is that it supports clinical meaningfulness, the severity levels and its multiple applications.
In this paper, we link pharmaceutical consumption (outpatient, specialist, and hospital) and the morbidity in a publicly funded healthcare system environment using CRGs as a risk adjustment system. In our estimations we use three different specifications. Then we test the predictive power of our different models and compare our results to others in the literature. Finally, as a policy implication and based on our findings, we advocate the use of risk adjustment in setting the premiums for pharmaceutical benefits. Table 1 shows the demographic characteristics of the population and the composition of the 9 CRG categories. The CRG system assigns one level of severity to each patient within the CRG category, so that in our database individuals are classified in 37 different risk groups (ACRG3), while the grouper allocates to 1081 groups at a more disaggregated level.
Estimation Methods
This paper estimates different models in order to predict drug expenditures in the subsequent year. Our objective is to examine the predictive properties of different models which use different information and how well they explain future cost. The basic model is characterized by: The typical specification in the risk adjustment literature is a simple specification, in which individuals are assigned to, say, age-sex cells. This specification is nonparametric in the sense that the parameters of the expectation conditional on age and sex are of free variation. In this paper we also consider two other specifications: a "parametric" specification in which the sex and age of each individual enter as independent variables in a nonlinear specification (sex, age, age 2 ) with a large number of zeros (39.65%).
Therefore, besides of using OLS, we also run a tobit estimation in our different model specifications.
The main indicator we use in order to measure how well the different model predicts is Although the normal use of risk adjustment is restricted to OLS linear nonparametric estimations, we have considered two more flexible alternative specifications, "parametric" and "flexible-parametric", in order to evaluate whether the role of demographic characteristics and its interaction and clinical conditions could be better explored. However, we have found very similar 2 R in the three specifications, meaning that with only demographic and CRG information, "nonparametric" models work as well as "parametric" or "flexible-parametric" models, being simpler to interpret and use.
Estimations from "nonparametric" models are very precise; and given the low correlation between age and sex, we obtain consistent and robust estimators. We also tried another "flexible-parametric" specification using the interaction of age and clinical conditions (CRG) but results were not improved. The 
Conclusions
The growth of pharmaceutical expenditure has created a need to improve its prediction in order to set appropriate budgets. In this paper we present the Clinical Risk Group classifications system (mutually exclusive categories providing individual clinical conditions and severity level) as an alternative to other morbidity classifications systems. Our results present CRGs as a risk adjuster with similar predicting power for 10 drug expenditures to other methods in prospective models and some higher proportion of variance explained in concurrent models. Provided the predictive power, the use of prospective risk adjustment is recommended in setting premiums for pharmaceutical benefits or in setting a budget constraint of public expenditures taking into account the characteristics or risks of the covered population. As a next step, once premiums and budgets are set adjusted to population characteristics and risks, risk adjustment is potentially profitable as a tool for controlling the drug expenditure and providing incentives for efficiency in the use of pharmaceutical benefits. 
